Noninvasive In Vivo Imaging of T-Cells during Cancer Immunotherapy Using Rare-Earth Nanoparticles

Boosting plant resilience: The promise of rare earth nanomaterials in growth, physiology, and stress mitigation

Rare earth elements (REE) have been extensively used in a variety of applications such as cell phones, electric vehicles, and lasers. REEs are also used as nanomaterials (NMs), which have distinctive features that make them suitable candidates for biomedical applications. In this review, we have highlighted the role of rare earth element nanomaterials (REE-NMs) in the growth of plants and physiology, including seed sprouting rate, shoot biomass, root biomass, and photosynthetic parameters. In addition, we discuss the role of REE-NMs in the biochemical and molecular responses of plants. Crucially, REE-NMs influence the primary metabolites of plants, namely sugars, amino acids, lipids, vitamins, enzymes, polyols, sorbitol, and mannitol, and secondary metabolites, like terpenoids, alkaloids, phenolics, and sulfur-containing compounds. Despite their protective effects, elevated concentrations of NMs are reported to induce toxicity and affect plant growth when compared with lower concentrations, and they not only induce toxicity in plants but also affect soil microbes, aquatic organisms, and humans via the food chain. Overall, we are still at an early stage of understanding the role of REE in plant physiology and growth, and it is essential to examine the interaction of nanoparticles with plant metabolites and their impact on the expression of plant genes and signaling networks.

Therapeutic efficacy of rare earth carbonate with chemoradiotherapy in late-stage non-small cell lung cancer: a cohort prospective study

Objective

To compare the therapeutic effects and adverse reactions of sterilizing rare earth carbonate combined with concurrent chemoradiotherapy and simple concurrent chemoradiotherapy in the treatment of late-stage non-small cell lung cancer (NSCLC), and to analyze the reasons for the differences.

Method

A total of 817 patients with pathologically diagnosed late-stage NSCLC from June 1, 2021 to December 30, 2022, in the affiliated hospital of Kunming University of Science and Technology, were selected. They were randomly divided into a control group of 394 people and an experimental group of 423 people. The control group was given concurrent chemoradiotherapy (cisplatin + etoposide), while the experimental group simultaneously took a low dose of sterilized rare earth carbonate (0.05mg/Kg). The χ² test and Fisher's test were used to compare the clinical pathological features, objective response rate (ORR), ECOG score, and adverse reactions of the two groups of patients, while survival analysis was used to compare the progression-free survival (PFS) of the two groups. Cox regression analysis was used to test factors related to prognosis.

Results

The differences in clinical pathological features between the two groups of patients were not statistically significant, with all P>0.05. The ORR of the control group was 45.18% (178/394), and the experimental group was 89.83% (380/423), with a statistically significant difference (P=0.001). After treatment, the ECOG score of the experimental group was lower than that of the control group, P<0.001. The adverse reaction grading of patients in both groups was below level 3 after treatment, and no treatment-related fatalities occurred. The risk of pulmonary infection and bone marrow suppression in the experimental group was lower than that in the control group.

Conclusion

In late-stage NSCLC patients, compared with simple concurrent chemoradiotherapy, the combination of concurrent chemoradiotherapy and sterilizing rare earth carbonate can significantly improve the short-term therapeutic effect and prognosis of patients, with good safety.